GR3005284T3 - - Google Patents

Info

Publication number
GR3005284T3
GR3005284T3 GR920401614T GR920401614T GR3005284T3 GR 3005284 T3 GR3005284 T3 GR 3005284T3 GR 920401614 T GR920401614 T GR 920401614T GR 920401614 T GR920401614 T GR 920401614T GR 3005284 T3 GR3005284 T3 GR 3005284T3
Authority
GR
Greece
Prior art keywords
alpha
double bond
androsten
aza
steroid
Prior art date
Application number
GR920401614T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3005284T3 publication Critical patent/GR3005284T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GR920401614T 1987-01-28 1992-07-29 GR3005284T3 (Direct)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/007,539 US4888336A (en) 1987-01-28 1987-01-28 Steroid 5-alpha-reductase inhibitors

Publications (1)

Publication Number Publication Date
GR3005284T3 true GR3005284T3 (Direct) 1993-05-24

Family

ID=21726780

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401614T GR3005284T3 (Direct) 1987-01-28 1992-07-29

Country Status (13)

Country Link
US (1) US4888336A (Direct)
EP (1) EP0277002B1 (Direct)
JP (1) JPS63192800A (Direct)
AT (1) ATE77388T1 (Direct)
AU (1) AU608560B2 (Direct)
CA (1) CA1325006C (Direct)
DE (1) DE3871965T2 (Direct)
DK (4) DK168525B1 (Direct)
ES (1) ES2042725T3 (Direct)
GR (1) GR3005284T3 (Direct)
IE (1) IE61594B1 (Direct)
PT (1) PT86652B (Direct)
ZA (1) ZA88549B (Direct)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US4814324A (en) * 1987-03-06 1989-03-21 Merck & Co., Inc. Sterol inhibitors of testosterone 5α-reductase
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5405978A (en) * 1989-05-30 1995-04-11 The Upjohn Company Oxidative preparation of 3,5-secoandrost-5-one-3,17 β-dioic acid
EP0943328B1 (en) * 1989-07-07 2004-06-16 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5250539A (en) * 1991-08-21 1993-10-05 Eli Lilly And Company Hexahydrobenzo[f]quinolinones
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones
EP0641356B1 (en) * 1991-12-20 1998-04-22 Glaxo Wellcome Inc. Inhibitors of 5-alpha-testosterone reductase
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
EP0641209A4 (en) * 1992-05-20 1995-08-23 Merck & Co Inc NEW 17-ESTER, AMID AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5-ALPHA REDUCTINE INHIBITORS.
US5510351A (en) * 1992-05-20 1996-04-23 Merck & Co., Inc. Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5 alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
CA2135173A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
AU668180B2 (en) * 1992-05-20 1996-04-26 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
AU672978B2 (en) * 1992-05-20 1996-10-24 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
AU680818B2 (en) * 1992-05-21 1997-08-14 Endorecherche Inc. Improved antiandrogens
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
JPH07506575A (ja) * 1992-05-21 1995-07-20 アンドルシェルシュ・インコーポレイテッド テストステロン５α−レダクターゼ活性の阻害剤
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
AU679769B2 (en) * 1993-06-28 1997-07-10 Merck & Co., Inc. 4-AZA-pregnane 5alpha-reductase isozyme 1 inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897202A (en) * 1956-03-19 1959-07-28 Monsanto Chemicals 3-keto-4-aza-delta5-steroids and method of preparing same
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
KR830000085B1 (ko) * 1978-04-13 1983-02-08 제임스 에프. 너우톤 5α-환원효소 억제제로서 유용한 4-아자-17-치환-5α-안드로스탄-3-온류의 제조방법
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors

Also Published As

Publication number Publication date
EP0277002A3 (en) 1988-10-26
CA1325006C (en) 1993-12-07
DK73594A (da) 1994-06-21
EP0277002B1 (en) 1992-06-17
DK168525B1 (da) 1994-04-11
DK196691D0 (da) 1991-12-05
AU608560B2 (en) 1991-04-11
IE880189L (en) 1988-07-28
PT86652B (pt) 1992-02-28
US4888336A (en) 1989-12-19
AU1077888A (en) 1988-08-04
ATE77388T1 (de) 1992-07-15
ZA88549B (en) 1988-07-27
DK37388A (da) 1988-07-29
ES2042725T3 (es) 1993-12-16
DK37388D0 (da) 1988-01-26
DK169438B1 (da) 1994-10-31
JPS63192800A (ja) 1988-08-10
IE61594B1 (en) 1994-11-16
PT86652A (pt) 1988-02-01
EP0277002A2 (en) 1988-08-03
DE3871965D1 (de) 1992-07-23
DK196691A (da) 1991-12-05
DE3871965T2 (de) 1993-01-14
DK169840B1 (da) 1995-03-13

Similar Documents

Publication Publication Date Title
IE880189L (en) Steroid 5-alpha-reductase inhibitors
GEP19981274B (en) Urinary follicle stimulating hormone, pharmaceutical composition, component of pharmaceutical composition
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
AU588202B2 (en) Dosage form for delivering acid sensitive beneficial agent
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
IE881269L (en) Steroids
GB8629981D0 (en) Tissue plasminogen activator compositions
IL72928A (en) Bronchodilating pharmaceutical compositions containing 5,6-dialkoxybenzothiophene-2-carboxylic acid
EP0293751A3 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
AU2726088A (en) Ampule for controlled administration of beneficial agent
IL80900A (en) Pharmaceutical composition containing fibrinolytic compounds and carbacyclin analogues for treatment of thrombosis
NZ239022A (en) Piperidyl ethers and thioethers; preparatory processes and pharmaceutical compositions
ZA899670B (en) Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
EP0266993A3 (en) Method and therapeutic compositions for the treatment of bleeding disorders
ZA87332B (en) Compositions containing fixed combinations
EP0256805A3 (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
IL87320A0 (en) Polyhydro derivatives of 10,11-dihydro-5-h-dibenzo-(a,d)cyclohepten-5,10-imine and pharmaceutical compositions containing them
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
IL86731A0 (en) Pharmaceutical compositions containing estradien-3-one derivatives and androst-2-ene-2-carbonitrile derivatives
AU645042B2 (en) Use of a polypeptide having the activity of gamma interferon for the preparation of pharmaceutical compositions intended for the treatment of primary cancers of the pleura